Post by Merck Group

Today, we announced a definitive agreement for the proposed acquisition of Bio-Techne for US$73 per share in cash. The proposed acquisition marks an important step in delivering our mid- to long-term strategy and strengthening our presence in fast-growing life science markets. Bio-Techne, based in Minneapolis, U.S., has deep scientific expertise and highly complementary capabilities across life science tools, analytical technologies, and next-generation biology. Through this planned acquisition, we will continue to strengthen our capabilities across our portfolio, accelerate innovation, and support our customers even more seamlessly across the scientific journey, from insights and discovery through development and manufacturing. Important information and the full release are available here: http://ms.spr.ly/6049vUilV